{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:56:20Z","timestamp":1781643380036,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Frankfurt School of Finance & Management gGmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Econ Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Value-based pricing (VBP) involves regulating the reimbursement or pricing of pharmaceuticals based on their therapeutic value. We adopt VBP as the policy context for this study. Unlike alternative approaches, VBP depends on an explicit relationship between price and incremental health outcomes and costs. This dependence makes VBP decisions especially sensitive to uncertainty about downstream costs and outcomes. A central question is whether\u2014and how far\u2014these components must be modeled beyond the trial period. A key gap is that the literature provides limited, generalizable conditions for when extrapolation is necessary for pricing conclusions versus when trial-period evidence is sufficient. This paper demonstrates the conditions under which it is possible to forgo modeling downstream costs beyond the clinical trial period for VBP purposes. It provides a series of specific mathematical proofs to support this approach. The proposed shortcuts reduce the burden and time required to produce evaluations. Furthermore, the shortcuts validate the robustness of decision models by allowing modelers to test whether applying these assumptions yields consistent results, enhancing the reliability of VBP methodologies.<\/jats:p>","DOI":"10.1186\/s13561-026-00757-5","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:35:52Z","timestamp":1773812152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Developing shortcut algorithms for value-based pricing of pharmaceuticals"],"prefix":"10.1186","volume":"16","author":[{"given":"Afschin","family":"Gandjour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"757_CR1","doi-asserted-by":"publisher","first-page":"103350","DOI":"10.1016\/j.critrevonc.2021.103350","volume":"162","author":"R Ananthakrishnan","year":"2021","unstructured":"Ananthakrishnan R, Green S, Previtali A, Liu R, Li D, LaValley M. Critical review of oncology clinical trial design under non-proportional hazards. Crit Rev Oncol Hematol. 2021;162:103350.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"757_CR2","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1586\/14737167.2015.1087317","volume":"15","author":"L Andronis","year":"2015","unstructured":"Andronis L. Analytic approaches for research priority-setting: issues, challenges and the way forward. Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):745\u201354.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"757_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0167-6296(92)90004-K","volume":"11","author":"S Birch","year":"1992","unstructured":"Birch S, Gafni A. Cost effectiveness\/utility analyses. Do current decision rules lead us to where we want to be? J Health Econ. 1992;11(3):279\u201396.","journal-title":"J Health Econ"},{"issue":"4","key":"757_CR4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/0167-6296(93)90006-Z","volume":"12","author":"S Birch","year":"1993","unstructured":"Birch S, Gafni A. Changing the problem to fit the solution: Johannesson and Weinstein\u2019s (mis) application of economics to real world problems J. Health Econ. 1993;12(4):469\u201376.","journal-title":"Health Econ"},{"issue":"6","key":"757_CR5","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","volume":"15","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. Value Health. 2012;15(6):835\u201342.","journal-title":"Value Health"},{"issue":"1","key":"757_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jhealeco.2006.06.002","volume":"26","author":"A Brennan","year":"2007","unstructured":"Brennan A, Kharroubi SA. Efficient computation of partial expected value of sample information using Bayesian approximation. J Health Econ. 2007;26(1):122\u201348.","journal-title":"J Health Econ"},{"key":"757_CR7","doi-asserted-by":"publisher","first-page":"118540","DOI":"10.1016\/j.atherosclerosis.2024.118540","volume":"396","author":"PM Burger","year":"2024","unstructured":"Burger PM, Dorresteijn JAN, Koudstaal S, Holtrop J, Kastelein JJP, Jukema JW, et al. Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: a meta-analysis of 60 randomized controlled trials. Atherosclerosis. 2024;396:118540.","journal-title":"Atherosclerosis"},{"issue":"6","key":"757_CR8","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/1043-2760(92)90032-V","volume":"3","author":"C Cooper","year":"1992","unstructured":"Cooper C, Melton LJ 3rd. Epidemiology of osteoporosis. Trends Endocrinol Metab. 1992;3(6):224\u20139.","journal-title":"Trends Endocrinol Metab"},{"key":"757_CR9","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, & Torrance GW. Methods for the economic evaluation of health care programmes (4th ed.). Oxford: Oxford University Press. 2015."},{"key":"757_CR10","unstructured":"European Commission, Directorate-General for Health and Food Safety. (n.d.). HTAR capacity building programme. European Commission. Retrieved December 22, 2025, from https:\/\/health.ec.europa.eu\/health-technology-assessment\/htar-capacity-building-programme_en"},{"key":"757_CR11","unstructured":"European Medicines Agency. (2025, January 10). New EU rules for health technology assessments become effective. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/news\/new-eu-rules-health-technology-assessments-become-effective"},{"key":"757_CR12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/hec.1370","volume":"18","author":"A Gandjour","year":"2009","unstructured":"Gandjour A. Aging diseases \u2013 do they prevent preventive health care from saving costs? Health Econ. 2009;18:355\u201362.","journal-title":"Health Econ"},{"issue":"6","key":"757_CR13","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s10198-012-0434-3","volume":"14","author":"A Gandjour","year":"2013","unstructured":"Gandjour A, Gafni A. Internal validation of models with several interventions. Eur J Health Econ. 2013;14(6):901\u20139.","journal-title":"Eur J Health Econ"},{"issue":"10","key":"757_CR14","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40273-018-0688-4","volume":"36","author":"A Gandjour","year":"2018","unstructured":"Gandjour A, Ostwald DA. Sacubitril\/Valsartan (LCZ696): a novel treatment for heart failure and its estimated cost effectiveness, budget impact, and disease burden reduction in Germany. Pharmacoeconomics. 2018;36(10):1285\u201396.","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"757_CR15","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1161\/01.STR.0000082382.42061.EE","volume":"34","author":"K Hardie","year":"2003","unstructured":"Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-year survival after first-ever stroke in the Perth community stroke study. Stroke. 2003;34(8):1842\u20136.","journal-title":"Stroke"},{"issue":"4","key":"757_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/0272989X9501500402","volume":"15","author":"DR Holtgrave","year":"1995","unstructured":"Holtgrave DR, Qualls NL. Threshold analysis and programs for prevention of HIV infection. Med Decis Making. 1995;15(4):311\u20137.","journal-title":"Med Decis Making"},{"key":"757_CR17","unstructured":"Latimer NR. Survival Analysis For Economic Evaluations Alongside Clinical Trials - Extrapolation with Patient-Level Data [Internet]. London: National Institute for Health and Care Excellence (NICE); 2013 Mar. NICE DSU Technical Support Document No. 14. PMID: 27905716. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK395885\/pdf\/Bookshelf_NBK395885.pdf"},{"issue":"1","key":"757_CR18","doi-asserted-by":"publisher","first-page":"e000094","DOI":"10.1136\/bmjmed-2021-000094","volume":"1","author":"NR Latimer","year":"2022","unstructured":"Latimer NR, Adler AI. Extrapolation beyond the end of trials to estimate long term survival and cost effectiveness. BMJ Med. 2022;1(1):e000094.","journal-title":"BMJ Med"},{"key":"757_CR19","first-page":"76","volume-title":"Cost-Effectiveness in Health and Medicine","author":"BR Luce","year":"1996","unstructured":"Luce BR, Manning WG, Siegel JE, Lipscomb J. Estimating costs in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996. p. 76\u2013213."},{"issue":"3","key":"757_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/0272989X13514774","volume":"34","author":"J Madan","year":"2014","unstructured":"Madan J, Ades AE, Price M, Maitland K, Jemutai J, Revill P, et al. Strategies for efficient computation of the expected value of partial perfect information. Med Decis Making. 2014;34(3):327\u201342.","journal-title":"Med Decis Making"},{"issue":"8","key":"757_CR21","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/archinte.166.8.884","volume":"166","author":"JR Madison","year":"2006","unstructured":"Madison JR, Spies C, Schatz IJ, Masaki K, Chen R, Yano K, et al. Proteinuria and risk for stroke and coronary heart disease during 27 years of follow-up: the Honolulu Heart Program. Arch Intern Med. 2006;166(8):884\u20139.","journal-title":"Arch Intern Med"},{"key":"757_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/acprof:oso\/9780190492939.003.0002","volume-title":"Cost-effectiveness in health and medicine","author":"DO Meltzer","year":"2016","unstructured":"Meltzer DO, Basu A, Sculpher MJ, et al. Theoretical foundations of cost-effectiveness analysis in health and medicine. In: Neumann PJ, Sanders GD, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press; 2016. p. 39\u201366."},{"issue":"19","key":"757_CR23","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1001\/archinte.159.19.2298","volume":"159","author":"B O'Brien","year":"1999","unstructured":"O\u2019Brien B, Levine M, Willan A, Goeree R, Haley S, Blackhouse G, et al. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Arch Intern Med. 1999;159(19):2298\u2013304.","journal-title":"Arch Intern Med"},{"key":"757_CR24","doi-asserted-by":"publisher","unstructured":"Paris, V., & Belloni, A. (2013). Value in pharmaceutical pricing (OECD Health Working Papers No. 63). OECD Publishing. https:\/\/doi.org\/10.1787\/5k43jc9v6knx-en","DOI":"10.1787\/5k43jc9v6knx-en"},{"issue":"2","key":"757_CR25","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jval.2012.10.018","volume":"16","author":"M Sadatsafavi","year":"2013","unstructured":"Sadatsafavi M, Bansback N, Zafari Z, Najafzadeh M, Marra C. Need for speed: an efficient algorithm for calculation of single-parameter expected value of partial perfect information. Value Health. 2013;16(2):438\u201348.","journal-title":"Value Health"},{"issue":"10","key":"757_CR26","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103.","journal-title":"JAMA"},{"issue":"17","key":"757_CR27","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609\u201320.","journal-title":"N Engl J Med."},{"issue":"5","key":"757_CR28","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1177\/0272989X15575286","volume":"35","author":"M Strong","year":"2015","unstructured":"Strong M, Oakley JE, Brennan A, Breeze P. Estimating the expected value of sample information using the probabilistic sensitivity analysis sample: a fast, nonparametric regression-based method. Med Decis Making. 2015;35(5):570\u201383.","journal-title":"Med Decis Making"},{"key":"757_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0047-2727(73)90002-9","volume":"2","author":"MC Weinstein","year":"1973","unstructured":"Weinstein MC, Zeckhauser R. Critical ratios and efficient allocation. J Public Econ. 1973;2:147\u201357.","journal-title":"J Public Econ"},{"issue":"2","key":"757_CR30","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.108.772962","volume":"118","author":"PW Wilson","year":"2008","unstructured":"Wilson PW, Bozeman SR, Burton TM, Hoaglin DC, Ben-Joseph R, Pashos CL. Prediction of first events of coronary heart disease and stroke with consideration of adiposity. Circulation. 2008;118(2):124\u201330.","journal-title":"Circulation"},{"issue":"4","key":"757_CR31","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40273-024-01450-3","volume":"43","author":"B Woods","year":"2025","unstructured":"Woods B, Palacios A, Sculpher M. A framework for using cost-effectiveness analysis to support pricing and reimbursement decisions for new pharmaceuticals in a context of evolving treatments, prices, and evidence. Pharmacoeconomics. 2025;43(4):363\u201373.","journal-title":"Pharmacoeconomics"}],"container-title":["Health Economics Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13561-026-00757-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-026-00757-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-026-00757-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:22:44Z","timestamp":1781641364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13561-026-00757-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["757"],"URL":"https:\/\/doi.org\/10.1186\/s13561-026-00757-5","relation":{},"ISSN":["2191-1991"],"issn-type":[{"value":"2191-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}